Lilly' Bamlanivimab & Etesevimab Reduce Hospitalizations & Death In Phase 3 Trial For Early COVID-19

(RTTNews) - Eli Lilly and Co.'s (LLY) bamlanivimab (LY-CoV555) 700 mg and etesevimab (LY-CoV016) 1400 mg together significantly reduced COVID-19 related hospitalizations and deaths in high-risk patients recently diagnosed with COVID-19, as per BLAZE-1 Phase 3 study. The therapy reduced risk of hospitalizations and death by 87 percent. The company...